Abstract 1512MO
Background
The efficacy of standard perioperative chemotherapy for patients (pts) with localized resectable G/GEJ cancer still needs to be further improved. This ongoing multicentred, randomized, open-label, phase III study compared efficacy and safety of perioperative C plus R and chemo (SOXRC) versus chemo alone (SOX) in localized resectable G/GEJ adenocarcinoma.
Methods
Pts with T3-4aN+M0 were randomized 1:1 to SOXRC (C 200 mg IV D1 + R 250 mg PO QD D1-21 + oxaliplatin 130 mg/m2 IV D1 + S-1 PO BID D1-14, Q3W) or SOX for 3 cycles pre/post D2 surgery, then R plus C (SOXRC) or S-1 (SOX) up to 17 cycles per investigator’s choice. Stratification was by tumour location (GEJ vs G) and bulky N (yes vs no). Blinded independent review committee (BIRC) assessed pathological complete response (pCR, ypT0) and investigators assessed EFS were primary endpoints. The secondary endpoints were major pathological response (MPR), total pCR (ypT0N0), R0 resection, DFS and OS. The planned sample size was 512 pts. The main analysis of pCR would be conducted after the first 360 randomized pts had the opportunity for D2 surgery.
Results
Of the first 360 randomized pts (SOXRC n=180; SOX n=180), 71.4% had gastric cancer and 28.6% had GEJ cancer; 66.7% had T4 and 100% had N+ with balanced baseline between arms. 179 pts received neoadjuvant therapy, 164 completed all neoadjuvant therapy and 155 underwent surgery (SOXRC); 177, 169 and 156 did the same (SOX). In the ITT population, BIRC-assessed pCR was 18.3% (95% CI 13.0-24.8) for SOXRC and 5.0% (95% CI 2.3-9.3) for SOX, with a statistically significant improvement of 13.7% (95% CI 7.2-20.1, p<0.0001); MPR was 51.1% vs 37.8%; tpCR was 16.7% vs 4.4%. In the surgery set, R0 resection was 98.7% (SOXRC) vs 94.2% (SOX). Surgical complications occurred at rates of 27.7% (SOXRC) and 30.1% (SOX). Preoperative grade ≥3 treatment-emergent adverse events occurred at rates of 36.3% (SOXRC) and 16.3% (SOX).
Conclusions
The trial showed perioperative C combined with R and chemo significantly improved pCR compared to chemo alone with a tolerable safety profile for localized resectable G/GEJ adenocarcinoma.
Clinical trial identification
NCT04208347.
Editorial acknowledgement
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
945MO - AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
Presenter: Ming Mo Hou
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
94MO - Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials
Presenter: Angela Lamarca
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
95MO - Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
Presenter: Meredith Pelster
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 945MO, 94MO and 95MO
Presenter: Lorenza Rimassa
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
LBA78 - Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
Presenter: Xiaotian Zhang
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA78 and 1512MO
Presenter: Hanneke van Laarhoven
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
LBA79 - GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Xiaotian Zhang
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA80 - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Presenter: Rui-Hua Xu
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
1513MO - A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
Presenter: Kei Muro
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA79, LBA80 and 1513MO
Presenter: Tania Fleitas
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast